ABL Bio Publishes Review Article on 4-1BB Antibodies in International Journal

ABL Bio announced on the 11th that it has published a review article on 4-1BB, a next-generation immuno-oncology target, in the international journal mAbs.

The article, which was released online on the 6th (local time), was published under the title, "Expanding the Horizon of Cancer Treatment with Next-Generation 4-1BB Antibodies: A Review of Molecular and Clinical Strategies to Maximize Efficacy and Ensure Safety." mAbs is an international journal covering antibody research and development.

According to the article, 4-1BB bispecific antibodies showed improved anticancer efficacy and a superior safety profile compared with existing monoclonal antibodies. 4-1BB bispecific antibodies are characterized by restricting the activation of immune T cells via 4-1BB signaling to the tumor microenvironment where cancer cells are present. They were introduced as an approach to overcome the limitations of the earlier 4-1BB monoclonal antibodies urelumab and utomilumab. The company expects 4-1BB to play an important role in future combination therapies, given that it also has a positive impact on maintaining long-term anticancer efficacy.

ABL Bio is developing various immuno-oncology drugs using its 4-1BB-based bispecific antibody platform "Grabody-T." ABL111, the most rapidly advancing candidate, is being developed with the goal of becoming a first-line standard treatment for patients with metastatic gastric cancer through combination therapy with the PD-1 inhibitor nivolumab and chemotherapy. The company explained that phase 1b clinical trials have confirmed improved anticancer efficacy compared with the existing standard of care. Another Grabody-T-based bispecific antibody, ABL503, is planned to be expanded from monotherapy trials to combination therapy trials.

Lee Sanghoon, CEO of ABL Bio, said, "We developed Grabody-T to overcome the limitations of existing 4-1BB monoclonal antibodies through a bispecific antibody approach that selectively activates T cells only in the tumor microenvironment," adding, "In the ongoing phase 1b clinical trial, ABL111 has demonstrated superior anticancer efficacy compared with the existing standard of care and has shown the potential to become 'best in class'."

This content was produced with the assistance of AI translation services.